Faces in 4 dimensions: Why do we care, and why the fourth dimension?

The purpose of this article is to describe a dynamic approach for 3-dimensional analyses of facial soft-tissue movements. The method and analysis have numerous applications but, most specifically, are used to assess diagnostic and treatment outcomes of soft-tissue surgery in patients with repaired cleft lip and palate.     

Neurocognition and conversion to psychosis in adolescents at high-risk

This study examined neurocognitive predictors of conversion to Axis I psychosis among adolescents at high-risk for psychosis (AHRP). There were no significant differences in neurocognitive performance between adolescents at high-risk for psychosis who converted (AHRP+) and adolescents at high-risk for psychosis who did not convert (AHRP−). Within-sex comparisons revealed a relation between risk status and performance among females, with AHRP+ performing below AHRP−, but this effect did not hold for males. Between-sex comparisons revealed AHRP− males performed worse than AHRP− females on several measures. Across groups, males performed better than their female counterparts on select measures. Results are discussed in terms of implications for use of neurocognitive profiles as bio-risk markers of psychosis, while considering sex differences.     

不同诱导方法诱导家蝇幼虫血淋巴中抗菌肽差异性的SDS-PAGE检测

目的 检测不同诱导方法(针刺,紫外,热诱导)诱导家蝇三龄幼虫血淋巴中的抗茵肽的差异性.方法 用不同诱导方法诱导家蝇三龄幼虫,提取血淋巴后,采用梯度乙腈洗脱,应用SDS-PAGE检测抗菌肽的差异性.结果 针刺与未诱导组无明显差异,热诱导组中30%乙腈洗脱组分中在30～71 KD中出现3个差异条带,紫外诱导组50%乙腈洗脱组分在16～20 KD中出现2个差异条带,60%乙腈洗脱组分中在16-20 KD中出现2个差异条带.结论 综合幼虫的成活率及操作的方便性,最佳的诱导方法为热诱导.     

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with plasmacytic differentiation and the MYD88 L265P mutation in >90% of cases. Traditionally, WM has been treated with chemoimmunotherapy. Recent trials have demonstrated the efficacy and safety of Bruton tyrosine kinase inhibitors in WM, both as monotherapy and in combination with other drugs. There is emerging evidence on the use of other agents including B-cell lymphoma 2 inhibitors and on the treatment of rare presentations of WM. In this update, the Medical and Scientific Advisory Group of Myeloma Australia reviews the available evidence on the treatment of WM since the last publication in 2017 and provides specific recommendations to assist Australian clinicians in the management of this disease.     

Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell

Patients with post-haemopoietic stem cell transplant or chimeric antigen receptor T -cell (CAR-T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally.     

Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more

Ibrutinib changed the landscape of treatment in Waldenström macroglobulinaemia (WM) with excellent responses; however, there are high rates of dose reduction due to adverse events. The impact of this reduced dosing is unclear with regards to outcomes. Sarosiek and colleagues provide valuable data in a very large retrospective study demonstrating that dose reduction is effective in managing adverse events in the majority, with equivalent, if not better, outcomes than those without dose reductions.     

注射用尤瑞克林治疗急性脑梗死的临床疗效观察

目的 观察尤瑞克林治疗急性脑梗死的临床疗效.方法 将符合入选条件的60例急性脑梗死惠者分为治疗组和对照组,每组30例.两组基础治疗相似,治疗组患者加用尤瑞克林,每日1次;分别给予治疗前后神经功能缺损评分和临床疗效比较,同时检测血常规、尿常规、肝肾功能及凝血功能等.结果 治疗组神经功能缺损评分较治疗前差异有统计学意义(P<0.05),疗效明显优于对照组,且无不良反应.结论 尤瑞克林治疗急性脑梗死疗效确切,安全可靠.